Puma Biotechnology Inc (PBYI)
NASDAQ: PBYIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 9.97 0.00%
PBYI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $514.65M
- P/E (TTM)
- 19.55
- Forward P/E
- 28.49
- EPS (TTM)
- $0.51
- Dividend yield
- None
- 52-week range
- 4.58 – 10.10
- Day range
- 9.45 – 9.99
- Volume / Avg
- 356.52K / 322.37K
- Beta
- —
- Shares outstanding
- 51.62M
- Next earnings
- Nov 5, 2026
52-week range
PBYI stock today
Puma Biotechnology (PBYI) closed at $9.97 on Oct 8, up 1.63% (+$0.16), versus the S&P 500's 0.47% decline. At this level, PBYI sits near the top of its 52-week range of $4.58 to $10.10: 1.3% below the high, set on Sep 30, 2026 and 117.7% above the low. PBYI is up 64.9% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 89.4%.
Puma Biotechnology trades at 19.5x its trailing twelve-month earnings per share of $0.51. Its forward P/E of 28.5x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Puma Biotechnology's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Puma Biotechnology
Company profilePuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Alan H. Auerbach
- Headquarters
- Los Angeles, CA
- Employees
- 179
- Website
- pumabiotechnology.com
Analyst forecast
ForecastConsensus (1 analysts)
none
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.06
Puma Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALTAltimmune Inc. | 2.60 | -2.26% | $505.75M | vs PBYI |
| MPLTMapLight Therapeutics Inc. | 9.15 | -2.24% | $508.52M | vs PBYI |
| DRUGBright Minds Biosciences Inc. | 52.00 | 0.00% | $512.93M | vs PBYI |
| EOLSEvolus Inc. | 7.80 | +0.78% | $515.19M | vs PBYI |
| CTNMContineum Therapeutics Inc. Class A | 13.18 | +3.54% | $495.85M | vs PBYI |
| CBIOCrescent Biopharma Inc. | 14.12 | +4.67% | $524.51M | vs PBYI |
| ARVNArvinas Inc. | 7.51 | +0.81% | $484.55M | vs PBYI |
| NGNENeurogene Inc. | 26.50 | +2.44% | $530.30M | vs PBYI |
Indexes, lists and sector
Puma Biotechnology stock FAQ
What is Puma Biotechnology's stock price today?
PBYI last traded at $9.97 as of Oct 8, 4:00 PM EDT, up 1.63% on the day. Prices are delayed at least 15 minutes.
When is Puma Biotechnology's next earnings date?
Puma Biotechnology is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.06.
What is PBYI's P/E ratio?
PBYI trades at a trailing P/E ratio of 19.55 and a forward P/E of 28.49.
Who is Puma Biotechnology's CEO?
Mr. Alan H. Auerbach is the chief executive officer of Puma Biotechnology Inc, which has about 179 employees.
What is the PBYI 52-week high?
The 52-week high for PBYI is $10.10 and the 52-week low is $4.58. The stock is currently 1.3% below its high.